Insufficient fluconazole levels in pediatric patients with cancer treated for invasive candidiasis
the ONA take:
According to a new study published in the journal Clinical Infectious Diseases, researchers have found that the fluconazole concentration in pediatric patients with cancer and invasive candidiasis is not sufficient for treatment with the currently recommended dosing regimen.
For the study, researchers identified 99 critically ill pediatric patients treated with fluconazole from January 2007 to October 2013. Of the 99 patients, 40% had subtherapeutic fluconazole plasma concentrations. Analyses demonstrated a significant and positive association between fluconazole trough concentration and dose (P < 0.001), weight (P = 0.009) and the serum urea concentration (P = 0.003).
In addition, there was a significant and negative association between fluconazole trough concentration and age (P = 0.004) and cancer as the underlying cause of invasive candidiasis (P = 0.003). In addition, they found that a higher fluconazole trough concentration was linked with a decreased duration to culture conversion (HR = 1.076, 95% CI 1.017 - 1.138, P = 0.011).
The findings suggest that a higher dose of fluconazole is necessary to achieve sufficient drug concentrations for the treatment of invasive candidiasis in critically ill pediatric patients with cancer.
Fluconazole in pediatric patients with cancer and invasive candidiasis is not sufficient for treatment.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|